The dual GLI1/p16 immunohistochemical panel thus emerges as a cost-effective and practical screening approach, enabling pathologists to effectively identify and distinguish GLI1-altered neoplasms and potentially guiding subsequent molecular testing and therapeutic decisions [12]. This evidence concerns the gene GLI1 and neoplasm.